ロード中...
Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults
The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8204976/ https://ncbi.nlm.nih.gov/pubmed/34178430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1938475 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|